Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto- placental unit: Role in intrauterine toxicity

Critical Reviews in Toxicology

Volumn 28, Issue 1, 1998, Pages 35-72

  Hakkola, Jukka ^a   Pelkonen, Olavi ^a   Fasanen, Markku ^a,b   Raunio, Hannu ^a  

^a UNIVERSITY OF OULU   (Finland)

^b NATIONAL AGENCY FOR MEDICINES   (Finland)

Author keywords

Drug metabolism; Fetus; In utero toxicity; Metabolic activation; Placenta; Pregnancy; Teratogenesis

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ENZYME ACTIVITY; FETOPLACENTAL UNIT; GENE EXPRESSION REGULATION; HUMAN; PRENATAL MORTALITY; REVIEW; TOXIN ANALYSIS; XENOBIOTIC METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FETUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; LIVER; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; RNA, MESSENGER; XENOBIOTICS;

RODENTIA;

EID: 0031909983     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408449891344173     Document Type: Review

References (240)

1. Mihaly, G. W. and Morgan, D. J., Placental drug transfer: effect of gestational age and species, Pharmacol. Ther., 23, 253-266, 1984.
2. Ward, R. M., Drug therapy of the fetus, J. Clin. Pharmacol., 33, 780-789, 1993.
3. Wells, P. G. and Winn, L. M., Biochemical toxicology of chemical teratogenesis, Crit. Rev. Biochem. Mol. Biol., 31, 1-40, 1996.
4. Juchau, M. R., Lee, Q. P., and Fantel, A. G., Xenobiotic biotransformation/bioactivation in organogenesis-stage conceptal tissues: implications for embryotoxicity and teratogenesis, Drug Metab. Rev., 24, 195-238, 1992.
5. Farrar, H. C. and Blumer, J. L., Fetal effects of maternal drug exposure, Annu. Rev. Pharmacol. Toxicol., 31, 525-547, 1991.
6. Peters, P. W. J., Garbis-Berkvens, H. M., and Bannigan, J. G., Drugs of choice in pregnancy: primary prevention of birth defects, Reprod. Toxicol., 7, 399-404, 1993.
7. Kuss, E., The fetoplacental unit of primates, Exp. Clin. Endocrinol., 102, 135-165, 1994.
8. Guengerich, F. P., Bioactivation and detoxication of toxic and carcinogenic chemicals, Drug Metab. Dispos., 21, 1-6, 1993.
9. Gonzalez, F. J. and Gelboin, H. V., Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins, Drug Metab. Rev., 26, 165-183, 1994.
10. Hinson, J. A. and Forkert, P.-G., Phase II enzymes and bioactivation, Can. J. Physiol. Pharmacol., 73, 1407-1413, 1995.
11. Raucy, J. L. and Carpenter, S. J., The expression of xenobiotic-metabolizing cytochromes P450 in fetal tissues, J. Pharmacol. Toxicol. Meth., 29, 121-128, 1993.
12. Pasanen, M. and Pelkonen, O., The expression and environmental regulation of P450 enzymes in human placenta, Crit. Rev. Toxicol., 24, 211-229, 1994.
13. Gonzalez, F. J. and Gelboin, H. V., Human cytochromes P450: evolution and cDNA-directed expression, Environ. Health Perspect., 98, 81-85, 1992.
14. Wrighton, S. A. and Stevens, J. C., The human hepatic cytochromes P450 involved in drug metabolism, Crit. Rev. Toxicol., 22, 1-21, 1992.
15. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W., P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6, 1-42, 1996.
16. Gonzalez, F. J., Human cytochromes P450: problems and prospects, Trends Pharmacol. Sci., 13, 346-352, 1992.
17. Raunio, H., Pasanen, M., Mäenpää, J., Hakkola, J., and Pelkonen, O., Expression of extrahepatic cytochrome P450 in humans, in Advances in Drug Metabolism in Man, Pacifici, G. M. and Fracchia, G.N., Eds., European Commission, Office for Official Publications of the European Communities, Luxembourg, 1995, 234.
18. Ioannides, C. and Parke, D. V., Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis, Drug Metab. Rev., 25, 485-501, 1993.
19. Nebert, D. W., Drug-metabolizing enzymes in ligand-modulated transcription, Biochem. Pharmacol., 47, 25-37, 1994.
20. Beresford, A. P., CYP1A1: friend of foe, Drug Metab. Rev., 25, 503-517, 1993.
21. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., and Hayashi, S., The CYP1A1 gene and cancer susceptibility, Crit. Rev. Oncol. Hematol., 14, 77-87, 1993.
22. 462: assessment of a role for the rare allele in carcinogenesis, Cancer Res., 56, 3926-3933, 1996.
23. Persson, I., Johansson, I., and Ingelman-Sundberg, M., In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility, Biochem. Biophys. Res. Commun., 231, 227-230, 1997.
24. Sengstag, C., Eugster, H.-P., and Würgler, F. E., High promutagen activating capacity of yeast microsomes containing human cytochrome P-450 1A and human NADPH-cytochrome P-450 reductase, Carcinogenesis, 15, 837-843, 1994.
25. Pelkonen, O. and Breimer, D. D., Role of environmental factors in the pharmacokinetics of drugs - considerations with respect to animal models, in Handbook of Experimental Pharmacology, Welling, P. G. and Balant, L. P., Eds., Karger, Basel, 1994, 289.
26. Nebert, D. W., The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects, Crit. Rev. Toxicol., 20, 137-152, 1989.
27. Idle, J. R., Armstrong, M., Boddy, A. V., Boustead, C., Cholerton, S., Cooper, J., Daly, A. K., Ellis, J., Gregory, W., Hadidi, H., Höfer, C., Holt, J., Leathart, J., McCracken, N., Monkman, S. C., Painter, J. E., Taber, H., Walker, D., and Yule, M., The pharmacogenetics of chemical carcinogenesis, Pharmacogenetics, 2, 246-258, 1992.
28. Raunio, H., Husgafvel-Pursiainen, K., Anttila, S., Hietanen, E., Hirvonen, A., and Pelkonen, O., Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - review, Gene, 159, 113-121, 1995.
29. Nebert, D. W., McKinnon, R. A., and Puga, A., Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer, DNA Cell Biol., 15, 273-280, 1996.
30. Farin, F. M., Pohlman, T. H., and Omiecinski, C. J., Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells, Toxicol. Appl. Pharmacol., 124, 1-9, 1994.
31. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther., 270, 414-423, 1994.
32. Guengerich, F. P., Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes, in Advances in Drug Metabolism in Man, Pacifici, G. M., and Fracchia, G. N., Eds., European Commission. Office for the Official Publications of the European Communities, Luxenbourg, 1995, 179.
33. Eaton, D. L., Gallagher, E. P., Bammler, T. K., and Kunze, K. L., Role of cytochrome P450IA2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity, Pharmacogenetics, 5, 259-274, 1995.
34. PA (P-450IA2), the phenacetin O-deetylase, is primarily reponsible for hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines, Proc. Natl. Acad. Sci. USA, 86, 7696-7700, 1989.
35. Guengerich, F. P., Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity, Toxicol. Lett., 70, 133-138, 1994.
36. Sutter, T. R., Tang, Y. M., Hayes, C. L., Wo, Y.-Y.P., Jabs, E. W., Li, X., Yin, H., Cody, C. W., and Greenlee, W. F., Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of a cytochrome that maps to chromosome 2, J. Biol. Chem., 269, 13092-13099, 1994.
37. Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., and Sutter, T. R., Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1, Cancer Res., 56, 2979-2984, 1996.
38. Hakkola, J., Pasanen, M., Pelkonen, O., Hukkanen, J., Evisalmi, S., Anttila, S., Rane, A., Mäntylä, M., Purkunen, R., Saarikoski, S., Tooming, M., and Raunio, H., Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis, 18, 391-397, 1997.
39. Spink, D. C., Hayes, C. L., Young, N. R., Christou, M., Sutter, T. R., Jefcoate, C. R., and Gierthy, J. F., The effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17b-estradiol 4-hydroxylase, J. Steroid Biochem. Mol. Biol., 51, 251-258, 1994.
40. Liehr, J. G., Ricci, M. J., Jefcoate, C. R., Hannigan, E. V., Hokanson, J. A., and Zhu, B. T., 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis, Proc. Natl. Acad. Sci. USA, 92, 9220-9224, 1995.
41. Savas, Ü., Bhattacharyya, K. K., Christou, M., Alexander, D. L., and Jefcoate, C. R., Mouse cytochrome P-450EF, representative of a new IB subfamily of cytochrome P-450s, J. Biol. Chem., 269, 14905-14911, 1994.
42. Martucci, C. P. and Fishman, J., P450 enzymes of estrogen metabolism, Pharmac. Ther., 57, 237-257, 1993.
43. Hoffman, S. M. G., Fernandez-Salguero, P., Gonzalez, F. J., and Mohrenweiser, H. W., Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19, J. Mol. Evolut., 41, 894-900, 1995.
44. Fernandez-Salguero, P., Hoffman, S. M. G., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., Pelkonen, O., Huang, J., Evans, W. E., Idle, J. R., and Gonzalez, F. J., A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles, Am. J. Hum. Genet., 57, 651-660, 1995.
45. Ding, S., Lake, B. G., Friedberg, T., and Wolf, C. R., Expression and alternative splicing of the cytochrome P-450 CYP2A7, Biochem. J. 306, 161-166, 1995.
46. Raunio, H., Syngelmä, T., Pasanen, M., Juvonen, R., Honkakoski, P., Kairaluoma, M. A., Sotaniemi, E. A., Lang, M. A., and Pelkonen, O., Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse, Biochem. Pharmacol., 37, 3889-3895, 1988.
47. Fernandez-Salguero, P. and Gonzalez, F. J., The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis, Pharmacogenetics, 5, S123-S128, 1995.
48. Rautio, A., Kraul, H., Kojo, A., Salmela, E., and Pelkonen, O., Interindividual variability of coumarin 7-hydroxylation in healthy individuals, Pharmacogenetics, 2, 227-233, 1992.
49. Cholerton, S., Idle, M. E., Vas, A., Gonzalez, F. J., and Idle, J. R., Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine, J. Chromatogr. 575, 325-330, 1992.
50. Imaoka, S., Yamada, T., Hiroi, T., Hayashi, K., Sakaki, T., Yabusaki, Y., and Funae, Y., Multiple forms of human P450 expressed in Saccharomyces cerevisiae, systematic characterization and comparison with those of the rat, Biochem. Pharmacol., 51, 1041-1050, 1996.
51. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Korzekwa, K., Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s, Arch. Biochem. Biophys. 290, 160-166, 1991.
52. Goldstein, J. A. and de Morais, S. M. F., Biochemistry and molecular biology of the human CYP2C subfamily, Pharmacogenetics, 4, 285-299, 1994.
53. Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., and Wolf, C. R., Genetic analysis of the human cytochrome P450 CYP2C9 locus, Pharmacogenetics, 6, 429-439, 1996.
54. Morel, F., Beaune, P. H., Ratanasavanh, D., Flinois, J.-P., Yang, C. S., Guengerich, F. P., and Guillouzo, A., Expression of cytochrome P-450 enzymes in cultured human hepatocytes, Eur. J. Biochem., 191, 437-444, 1990.
55. Leo, M. A., Lasker, J. M., Raucy, J. L., Kim, C.-I., Black, M., and Lieber, C. S., Metabolism of retinol and retinoic acids by human liver cytochrome P450IIC8, Arch. Biochem. Biophys., 269, 305-312, 1989.
56. Cholerton, S., Daly, A. K., and Idle, J. R., The role of individual human cytochromes P450 in drug metabolism and clinical response, Trends Pharmacol. Sci., 13, 434-439, 1992.
57. Heim, M. H. and Meyer, U. A., Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6, Genomics, 14, 49-58, 1992.
58. Ingelman-Sundberg, M. and Johansson, I., The molecular genetics of the human drug metabolizing cytochrome P450s, in Advances in Drug Metabolism in Man, Pacifici, G. M. and Fracchia, G. N. Eds., Office for Official Publications of the European Communities, Luxemburg, 1995, 534.
59. Song, B.-J., Gelboin, H. V., Park, S.-S., Yang, C. S., and Gonzalez, F. J., Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s, J. Biol. Chem., 261, 16689-16697, 1986.
60. Ronis, M. J. J., Lindros, K. O., and Ingelman-Sundberg, M., The CYP2E subfamily, in Cytochromes P450. Metabolic and Toxicological Aspects, Ioannides, C. and Parke, D. V., Eds., CRC Press, Boca Raton, 1996, 211.
61. Koop, D. R. Oxidative and reductive metabolism by cytochrome P450 2E1, FASEB J., 6, 724-730, 1992.
62. Patten, C., Thomas, P. E., Guy, R., Lee, M., Gonzalez, F. J., Guengerich, F. P., and Yang, C. S., Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics, Chem. Res. Toxicol., 6, 511-518, 1993.
63. Peter, R., Böcker, R. G., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C.-S., Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1, Chem. Res. Toxicol., 3, 566-573, 1990.
64. Nhamburo, P. T., Kimura, S., McBride, O. W., Kozak, C. A., Gelboin, H. V., and Gonzalez, F. J., The human CYP2F gene family: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping, Biochemistry, 29, 5491-5499, 1990.
65. Thornton-Manning, J. R., Ruangyuttikarn, W., Gonzalez, F. J., and Yost, G. S., Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s, Biochem. Biophys. Res. Commun., 181, 100-107, 1991.
66. Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., and Zeldin, D. C., Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart, J. Biol. Chem., 271, 3460-3468, 1996.
67. Yamazaki, H., Inui, Y., Wrighton, S. A., Guengerich, F. P., and Shimada, T., Pro-carcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes, Carcinogenesis, 16, 2167-2170, 1995.
68. Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A., and Guzelian, P. S., Identification of an inducible form of cytochrome P-450 in human liver, Proc. Natl. Acad. Sci. USA, 82, 6310-6314, 1985.
69. Neuvonen, P. J., Interactions in first-pass metabolism and variability in drug response, in Clinical Measurement in Drug Evaluation, Nimmo, W. S. and Tucker, G. T. Eds., John Wiley & Sons Ltd, 1995, 301.
70. Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., and Watkins, P. B., CYP3A gene expression in human gut epithelium, Pharmacogenetics, 4, 247-259, 1994.
71. Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., and Gonzalez, F. J., Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver, J. Biol. Chem., 264, 10388-10395, 1989.
72. Wrighton, S. A., Ring, B. J., Watkins, P. B., and VandenBranden, M., Identification of a polymorphically expressed member of the human cytochrome P-450III family, Mol. Pharmacol., 86, 97-05, 1989.
73. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., and VandenBranden, M., Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3), Mol. Pharmacol., 38, 207-213, 1990.
74. Schuetz, E. G., Schuetz, J. D., Grogan, W. M., Naray-Fejes-Toth, A., Fejes-Toth, G., Raucy, J., Guzelian, P., Gionela, K., and Watlington, C.O., Expression of cytochrome P450 3A in amphibian, rat, and human kidney, Arch. Biochem. Biophys., 294, 206-214, 1992.
75. Kivistö, K. T., Griese, E.-U., Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P., and Kroemer, H. K., Expression of cytochrome P4503A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumors, Naunyn-Schmiedeberg Arch. Pharmacol., 353, 207-212, 1996.
76. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., Kato, R., and Kanakubo, Y., Purification and properties of cytochrome P-450 from homogenates of human fetal livers, Arch. Biochem. Biophys., 241, 275-280, 1985.
77. Kitada, M. and Kamataki, T. Cytochrome P450 in human fetal liver: significance and fetal specific expression, Drug Metab. Rev., 26, 305-323, 1994.
78. Komori, M., Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., and Kamataki, T., Fetus-specific expression of a form of cytochrome P-450 in human livers, Biochemistry, 29, 4430-4433, 1990.
79. Schuetz, J. D., Beach, D. L., and Guzelian, P. S., Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver, Pharmacogenetics, 4, 11-20, 1994.
80. Hakkola, J., Pasanen, M., Purkunen, R., Saarikoski, S., Pelkonen, O., Mäenpää, J., Rane, A., and Raunio, H., Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver, Biochem. Pharmacol., 48, 59-64, 1994.
81. Greuet, J., Pichard, L., Bonfils, C., Domergue, J., and Maurel, P., The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture, Biochem. Biophys. Res. Commun., 225, 689-694, 1996.
82. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., and Kanakubo, Y., Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations, Biochem. Pharmacol., 36, 453-456, 1987.
83. Nhamburo, P. T., Gonzalez, F. J., McBride, O. W., Gelboin, H. V., and Kimura, S., Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression, and chromosome mapping, Biochemistry, 28, 8060-8066, 1989.
84. Yokotani, N., Sogawa, K., Matsubara, S., Gotoh, O., Kusunose, E., Kusunose, M., and Fujii-Kuriyama, Y., cDNA cloning of cytochrome P-450 related to P-450p-2 from the cDNA library of human placenta: gene structure and expression, Eur. J. Biochem., 187, 23-29, 1990.
85. McKinnon, R. A., Burgess, W. M., Gonzalez, F. J., Gasser, R., and McManus, M. E., Species-specific expression of CYP4B1 in rabbit and human gastrointestinal tissues, Pharmacogenetics, 4, 260-270, 1994.
86. Denison, M. S. and Whitlock, J. P. J., Xenobiotic-inducible transcription of cytochrome P450genes, J. Biol. Chem., 270, 18175-18178, 1995.
87. Chen, D., Lepard, G., and Kemper, B., A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4, J. Biol. Chem., 269, 5420-5427, 1994.
88. Gonzalez, F. J., Liu, S.-Y., and Yano, M., Regulation of cytochrome P450 genes: molecular mechanisms, Pharmacogenetics, 3, 51-57, 1993.
89. Okey, A. B., Enzyme induction in the cytochrome P-450 system, Pharmacol. Ther., 45, 241-298, 1990.
90. Hankinson, O., The aryl hydrocarbon receptor complex, Annu. Rev. Pharmacol. Toxicol., 35, 307-340, 1995.
91. Pohjanvirta, R. and Tuomisto, J., Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal models, Pharmacol. Rev. 46, 483-549, 1994.
92. Okey, A. B., Riddick, D. S., and Harper, P. A., The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds, Toxicol. Lettt., 70. 1-22, 1994.
93. Peters, J. M. and Wiley, L. M., Evidence that murine preimplantation embryos express aryl hydrocarbon receptor, Toxicol. Appl. Pharma col., 134, 214-221, 1995.
94. Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S. T., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., and Gonzalez, F. J., Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor, Science, 268, 722-726, 1995.
95. Schmidt, J. V., Su, G. H.-T., Reddy, J. K., Simon, M. C., and Bradfield, C. A., Characterization of a murine Ahr null allele: animal model for the toxicity of halogenated dioxins and biphenyls, Proc. Natl. Acad. Sci. USA, 93, 6731-6736, 1996.
96. Waxman, D. J. and Azaroff, L., Phenobarbital induction of cytochrome P-450 gene expression, Biochem. J., 281, 577-592, 1992.
97. Lake, B. G. Peroxisome proliferation: current mechanisms relating to non-genotoxic carcinogenesis, Toxicol. Lettt., 82/83, 673-681, 1995.
98. Schuetz, J. D., Schuetz, E. G., Thottassery, J. V., Guzelian, P. S., Strom, S., and Sun, D., Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells, Mol. Pharmacol., 49, 63-72, 1996.
99. Ingelman-Sundberg, M., Ethanol-inducible cytochrome P450 2E1. Regulation, radical formation and toxicological importance, in Free Radicals: From Basic Science to Medicine, Poli, G., Albano, E., and Dianzani, M. U., Eds., Birkhäuser, Basel, 1993, 287.
100. Lieber, C. S., Alcohol and the liver: 1994 update, Gastroenterology, 106, 1085-1105, 1994.
101. Whyatt, R. M. and Perera, F. P., Application of biologic markers to studies of environmental risks in children and the developing fetus, Environ. Health Perspect., 103(Suppl.6), 105-110, 1995.
102. Pelkonen, O., Biotransformation of xenobiotics in the fetus, Pharmacol. Ther., 10, 261-281, 1980.
103. Itoh, S., Satoh, M., Abe, Y., Hashimoto, H., Yanagimoto, T., and Kamataki, T., A novel form of mouse cytochrome P450 3A (Cyp3a-16). Its cDNA cloning and expression in fetal liver, Eur. J. Biochem., 226, 877-882, 1994.
104. Nebert, D. W. and Gelboin, H. V., The in vivo and in vitro induction of aryl hydrocarbon hydroxylase in mammalian cells of different species, tissues, strains, and developmental and hormonal status, Arch. Biochem. Biophys., 134, 76-89, 1969.
105. Hulla, J. E. and Juchau, M. R., Developmental aspects of P450IIIA: prenatal activity and inducibility, Drug Metab. Rev., 20, 765-779, 1989.
106. Miller, M. S., Transplacental lung carcinogenesis: a pharmacogenetic mouse model for the modulatory role of cytochrome P450 1A1 on lung cancer initiation, Chem. Res. Toxicol., 7, 471-481, 1994.
107. Yaffe, S. J., Rane, A., Sjöqvist, F., Boréus, L.-O., and Orrenius, S., The presence of a monooxygenase system in human fetal liver microsomes, Life Sci., 9, 1189-1200, 1970.
108. Krauer, B. and Dayer, P., Fetal drug metabolism and its possible clinical inplications, Clin. Pharmacokinet., 21. 70-80, 1991.
109. Leroux, J. P., Cresteil, T., and Marie, S., Ontogeny and regulation of drug metabolism in humans, Dev. Pharmacol. Ther., 13, 63-69, 1989.
110. Pasanen, M., Pelkonen, O., Kauppila, A., Park, S. S., Friedman, F. K., and Gelboin, H. V., Characterization of human fetal hepatic cytochrome P-450-associated 7-ethoxyresorufin O-deethylase and aryl hydrocarbon hydroxylase activities by monoclonal antibodies, Dev. Pharmacol. Ther., 10, 125-132, 1987.
111. Yang, H.-Y.L., Namkung, M. J., and Juchau, M. R., Expression of functional cytochrome P4501A1 in human embryonic hepatic tissues during organogenesis, Biochem. Pharmacol., 49, 717-726, 1995.
112. Murray, G. I., Foster, C. O., Barnes, T. S., Weaver, R. J., Snyder, C. P., Ewen, S. W. B., Melvin, W. T., and Burke, M. D., Cytochrome P450IA expression in adult and fetal human liver, Carcinogenesis, 13, 165-169, 1992.
113. Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng, Y.-F., Guengerich, F. P., and Inui, Y., Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs, Drug Metab. Dispos., 24, 515-522, 1996.
114. Omiecinski, C. J., Redlich, C. A., and Costa, P., Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues, Cancer Res., 50, 4315-4321, 1990.
115. Mäenpää, J., Rane, A., Raunio, H., Honkakoski, P., and Pelkonen, O., Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse, Biochem. Pharmacol., 45, 899-907, 1993.
116. Cazeneuve, C., Pons, G., Rey, E., Treluyer, J.-M., Cresteil, T., Thiroux, G., D'athis, P., and Olive, G., Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults, Br. J. Clin. Pharmacol., 37, 405-412, 1994.
117. Ratanasavanh, D., Beaune, P., Morel, F., Flinois, J.-P., Guengerich, F. P., and Guillouzo, A., Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age, Hepatology, 13, 1142-1151, 1991.
118. Cresteil, T., Beaune, P., Kremers, P., Celier, C., Guengerich, F. P., and Leroux, J. P., Immunoquantification of epoxide hydroxylase and cytochrome P-450 isozymes in fetal and adult human liver microsomes, Eur. J. Biochem., 151, 345-350, 1985.
119. Pons, C., Dansette, P. M., Amar, C., Jaouen, M., Wolf, C. R., Gregeois, J., Homberg, J. C., and Mansuy, D., Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 HC11, J. Pharmacol. Exp. Ther., 259, 1328-1334, 1991.
120. Umberhauer, D. R., Martin, M. V., Lloyd, R. S., and Guengerich, F. P., Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase, Biochemistry, 26, 1094-1099, 1987.
121. Shimada, T., Misono, K. S., and Guengerich, F. P., Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism, J. Biol. Chem., 261, 909-921, 1986.
122. Ladona, M. G., Lindström, B., Thyr, C., Dun-Ren, P., and Rane, A., Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man, Br. J. Clin. Pharmacol., 32, 295-302, 1991.
123. Treluyer, J.-M., Jacqz-Aigrain, E., Alvarez, F., and Cresteil, T., Expression of CYP2D6 in developing human liver, Eur. J. Biochem., 202, 583-588, 1991.
124. Jacqz-Aigrain, E. and Cresteil, T., Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies, Dev. Pharmacol. Ther., 18, 161-168, 1992.
125. Komori, M., Nishio, K., Fujitani, T., Ohi, H., Kitada, M., Mima, S., Itahashi, K., and Kamataki, T., Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers, Arch. Biochem. Biophys., 272, 219-225, 1989.
126. Jones, S. M., Boobis, A. R., Moore, G. E., and Stanier, P. M., Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples, Biochem. Pharmacol., 43, 1876-1879, 1992.
127. Wrighton, S. A., Molowa, D. T., and Guzelian, P. S., Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult, Biochem. Pharmacol., 37, 3053-3055, 1988.
128. Vieira, I., Sonnier, M., and Cresteil, T., Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period, Eur. J. Biochem., 238, 476-483, 1996.
129. Wu, D. and Cederbaum, A. I., Expression of cytochrome P4502E1 in rat fetal hepatocyte culture, Mol. Pharmacol., 49, 802-807, 1996.
130. Carpenter, S. J., Lasker, J. M., and Raucy, J. L., Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes, Mol. Pharmacol., 49, 260-268, 1996.
131. Yang, H.-Y.L., Lee, Q. P., Rettie, A. E., and Juchau, M. R., Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis, Mol. Pharmacol., 46, 922-928, 1994.
132. Wrighton, S. A. and VandenBranden, M., Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family, Arch. Biochem. Biophys., 268, 144-151, 1989.
133. Komori, M., Nishio, K., Ohi, H., Kitada, M., and Kamataki, T., Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450, J. Biochem., 105, 161-163, 1989.
134. Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., and Cresteil, T., Expression of CYP3A in the human liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth, Eur. J. Biochem., 247, 625-634, 1997.
135. Mäenpää, J., Pelkonen, O., Cresteil, T., and Rane, A., The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver, J. Steroid. Biochem. Molec. Biol., 44, 61-67, 1993.
136. Cresteil, T., Beaune, P., Kremers, P., Flinois, J.-P., and Leroux, J.-P., Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P 450, Pediatr. Pharmacol., 2, 199-207, 1982.
137. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., and Kanakubo, Y., P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16a-hydroxylase of dehydroepiandrosterone 3-sulfate, J. Biol. Chem., 262, 13534-13537, 1987.
138. Rane, A., Henningson, S., Ask, B., and Ladona, M. G., Comparison of human fetal hepatic and adrenal cytochrome P450 activities with some major gestational steroids and ethylmorphine as substrates, J. Steroid. Biochem. Molec., Biol. 43, 335-341, 1992.
139. Ryan, K. J., Placental synthesis of steroid hormones, in Maternal-Fetal Endocrinology, Tulchinsky, D. and Ryan, K. J., Eds., W. B. Saunders Company, Philadelphia, 1980, 3.
140. Kitamura, R., Sato, K., Sawada, M., Itoh, S., Kitada, M., Komori, M., and Kamataki, T., Stable expression of cytochrome P450IIIA7 cDNA in human breast cancar cell line MCF-7 and its application to cytotoxicity testing, Arch. Biochem. Biophys., 292, 136-140, 1992.
141. Sakuma, T., Kitamura, R., Yokoi, T., and Kamataki, T., Efficient complementary DNA directed expression of human fetal liver cytochrome P450 (CYP3A7) in insect cells using baculovirus, Arch. Biochem. Biophys., 11520, 22828-4654, 1995.
142. Li, Y., Yokoi, T., Kitamura, R., Sasaki, M., Gunji, M., Katsuki, M., and Kamataki, T., Establishment of transgenic mice carrying human fetus-specific CYP3A7, Arch. Biochem. Biophys., 329, 235-240, 1996.
143. Kitada, M., Taneda, M., Itahashi, K., and Kamataki, T., Four forms of cytochrome P-450 in human fetal livers: purification and their capacity to activate promutagens, Jpn. J. Cancer Res., 82, 426-432, 1991.
144. Kitada, M., Kato, T., Ohmori, S., Kamataki, T., Itahashi, K., Guengerich, F. P., Rikihisa, T., and Kanakubo, Y., Immunochemical characterization and toxicological significance of P-450HFLb purified from human fetal livers, Biochim. Biophys. Acta, 1117, 301-305, 1992.
145. Kamataki, T., Kitada, M., Komori, M., Yokoi, T., and Kitamura, R., Human fetal liver cytochrome P-450: capacity to form genotoxic metabolites, Tohoku. J. Exp. Med., 168, 89-95, 1992.
146. Pasanen, M., Rannala, Z., Tooming, A., Sotaniemi, E.A., Pelkonen, O., and Rautio, A., Hepatitis A impairs the function of human hepatic CYP2A6 in vivo, Toxicology, 1997.
147. Rifkind, A. B., Tseng, L., Hirsch, M., and Lauersen, N. H., Aryl hydrocarbon hydroxylase activity and microsomal cytochrome content of human fetal tissues, Cancer Res., 38, 1572-1577, 1978.
148. Pelkonen, O., Arvela, P., and Kärki, N. T., 3,4-Benzpyrene and N-demetylaniline metabolizing enzymes in the immature human foetus and placenta, Acta Pharmacol. Toxicol., 30, 385-395, 1971.
149. Pelkonen, O., Differential inhibition of aryl hydrocarbon hydroxylase in human foetal liver, adrenal gland and placenta, Acta Pharmacol. Toxicol., 41, 306-316, 1977.
150. Lee, Q. P., Fantel, A. G., and Juchau, M. R., Human embryonic cytochrome P450s: phenoxazone ethers as probes for expression of functional isoforms during organogenesis, Biochem. Pharmacol., 42, 2377-2385, 1991.
151. Namkung, M. J., Yang, H.-Y. L., and Juchau, M. R., Cytochrome P-450-dependent biotransformation of 2-acetylaminofluorene in cell-free preparations of human embryonic hepatic, adrenal, renal, pulmonary, and cardiac tissues, Drug Metab., Dispos., 22, 331-337, 1994.
152. Kato, T., Nakasa, H., Ohmori, S., Kamataki, T., Itahashi, K., Shimada, T., Rikihisa, T., and Kitada, M., Possible occurence of P450 related to P450 HFLb in extrahepatic tissues of human fetuses and its contribution to metabolic activation of promutagens, Mutat. Res., 310, 73-77, 1994.
153. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., Kato, R., and Kanakubo, Y., Immunochemical examination of cytochrome P-450 in various tissues of human fetuses using antibodies to human fetal cytochrome P-450, P-450HFLa, Biochem. Biophys. Res. Commun., 131, 1154-1159, 1985.
154. Ladona, M. G., Park, S.-S., Gelboin, H. V., Hammar, L., and Rane, A., Monoclonal antibody directed detection of cytochrome P-450 (PCN) in human fetal liver, Biochem. Pharmacol., 37, 4735-4741, 1988.
155. Gilham, D. E., Cairns, W., Paine, M. J. I., Modi, S., Poulsom, R., Roberts, G. C. K., and Wolf, C. R., Metabolism of MTPT by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization, Xenobiotica, 21, 111-125, 1997.
156. Boutelet-Bochan, H., Huang, Y., and Juchau, M. R., Expression of CYP2E1 during embryogenesis and fetogenesis in human cephalic tissues: Implications for the fetal alcohol syndrome, Biochem. Biophys. Res. Commun., 238, 443-447, 1997.
157. Stoilov, I., Akarsu, A. N., and Sarfarazi, M., Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21, Hum. Mol. Genet., 6, 641-647, 1997.
158. Jounaidi, Y., Guzelian, P. S., Maurel, P., and Vilarem, M.-J., Sequence of the 5′-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7, Biochem. Biophys. Res. Commun., 205, 1741-1747, 1994.
159. Schuetz, E. G., Schuetz, J. D., Strom, S. C., Thompson, M. T., Fisher, R. A., Molowa, D. T., Li, D., and Guzelian, P. S., Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes, Hepatology, 18, 1254-1262, 1993.
160. Itoh, S., Yanagimoto, T., Tagawa, S., Hashimoto, H., Kitamura, R., Nakajima, Y., Okochi, T., Fujimoto, S., Uchino, J., and Kamataki, T., Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLa)-related gene(s) and interaction of transcriptional regulatory factor with its DNA
161. Wiebkin, P., Dees, J. H., Mathis, J. M., and Prough, R. A., Drug metabolism by isolated fetal human hepatocytes in suspension and primary culture, Drug Metab. Dispos., 13, 163-168, 1985.
162. Lindros, K. O., Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver, Gen. Pharmacol., 28, 191-196, 1997.
163. Murray, G. I., Barnes, T. S., Sewell, H. F., Ewen, S. W. B., Melvin, W. T., Shaw, P. M., Fowler, J., and Burke, M. D., Cytochrome P-450 localization in normal human adult and foetal liver by immunocytochemistry using a monoclonal antobody against human cytochrome P-450, Histochem. J., 19, 537-545, 1987.
164. Pelkonen, O., Detoxification and toxification processes in the human feto-placental unit, in Drugs and Pregnancy, Maternal Drug Handling - Fetal Drug Exposure, Krauer, B., Krauer, F., Hytten, F. E., and del Pozo, E., Eds., Academic Press, London, 1984, 63.
165. Iannaccone, P. M., Bossert, N. L., and Connelly, C. S., Disruption of embryonic and fetal development due to preimplantation chemical insults: a critical review, Am. J. Obstet. Gynecol., 157, 476-484, 1978.
166. Coceani, F., Control of the ductus arteriosus - a new function for cytochrome P450, endothelin and nitric oxide, Biochem. Pharmacol., 48, 1315-1318, 1994.
167. Coceani, F., Kesley, L., Ackerley, C., Rabinovitch, M., and Gelboin, H. V., Cytochrome P450 during ontogenic development: occurrence in the ductus arteriosus and other tissues, Can. J. Physiol. Pharmacol., 72, 217-226, 1994.
168. Pasanen, M. and Pelkonen, O., Human placental xenobiotic and steroid biotransformations catalyzed by cytochrome P450, epoxide hydrolase, and glutathione S-transferase activities and their relationships to maternal cigarette smoking, Drug Metab. Rev., 21, 427-461, 1989.
169. Pasanen, M. and Pelkonen, O., Xenobiotic and steroid-metabolizing monooxygenases catalysed by cytochrome P450 and glutathione S-transferase conjugations in the human placenta and their relationships to maternal cigarette smoking, Placenta, 11, 75-85, 1990.
170. Welch, R. M., Harrison, Y. E., Conney, A. H., Poppers, P. J., and Finster, M., Cigarette smoking: stimulatory effect on metabolism of 3,4-benzopyrene by enzymes in human placenta, Science, 160, 541-542, 1968.
171. Welch, R. M., Harrison, Y. E., Gommi, B. W., Poppers, P. J., Finster, M., and Conney, A. H., Stimulatory effect of cigarette smoking on the hydroxylation of 3,4,-benzpyrene and the N-demethylase of 3-methyl-4-monomethylaminoazobenzene by enzymes in human placenta, Clin. Pharmacol. Ther., 10, 100-109, 1969.
172. Nebert, D. W., Winker, J., and Gelboin, H. V., Aryl hydrocarbon hydroxylase activity in human placenta from cigarette smoking and nonsmoking women, Cancer Res., 29, 1763-1769, 1969.
173. Wong, T. K., Everson, R. B., and Hsu, S.-T., Potent induction of human placental monooxygenase activity by previous dietary exposure to polyclorinated biphenyls and their thermal degradation products, Lancet, I, 721-724, 1985.
174. Juchau, M. R., Human placental hydroxylation of 3,4,-benzpyrene during early gestation and at term, Toxicol. Appl. Pharmacol., 18, 665-675, 1971.
175. Sanyal, M. K., Li, Y.-L., Biggers, W. J., Satish, J., and Barnea, E. R., Augmentation of polynuclear aromatic hydrocarbon metabolism of human placental tissues of first-trimester pregnancy by cigarette smoke exposure, Am. J. Obstet. Gynecol., 168, 1587-1597, 1993.
176. Pasanen, M., Vahakangas, K., Sotaniemi, E. A., and Pelkonen, O., The effect of cigarette smoking on drug metabolism in the liver and placenta: the use of cotinine in verifying smoking status, Eur. J. Drug Metab. Pharmacokin., 13, 41-45, 1988.
177. Manchester, D. K., Range of environmentally responsive monooxygenase activities in human placental microsomes determined by direct fluorescence techniques, Biochem. Pharmacol. 30, 757-762, 1981.
178. Jacobson, M., Levin, W., Poppers, P., Wood, A. W., and Conney, A. H., Comparison of the O-dealkylation of 7-ethoxycoumarin and the hydroxylation of benzo(a)pyrene in human placenta, Clin. Pharmacol. Ther., 16, 701-710, 1974.
179. Pelkonen, O. and Moilanen, M.-L., The specificity and multiplicity of human placental xenobiotic-metabolizing monooxygenase system studied by potential substrates, inhibitors and gel electrophoresis, Med. Biol., 57, 306-312, 1979.
180. Toma, Y., Higashiyama, T., Yarborough, C., and Osawa, Y., Diverse functions of aromatase: O-deethylation of 7-ethoxycoumarin, Endocrinology, 137, 3791-3796, 1996.
181. Hakkola, J., Mäenpää, J., Mayer, R. T., Park, S. S., Gelboin, H. V., and Pelkonen, O., 7-alkoxyquinoline O-dealkylation by microsomes from human liver and placenta, Br. J. Clin. Pharmacol., 34, 415-420, 1992.
182. Berry, D. L., Zachariah, P. K., Slaga, T. J., and Juchau, M. R., Analysis of the biotransformation of benzo[a]pyrene in human fetal and placental tissues with high-pressure liquid chromatography, Eur. J. Cancer, 13, 667-675, 1977.
183. Rettie, A. E., Heimark, L., Mayer, R. T., Burke, M. D., Trager, W. F., and Juchau, M. R., Stereo and regioselective hydroxylation of warfarin and selective O-dealkylation of phenoxazone ethers in human placenta, Biochem. Biophys. Res. Commun., 126, 1013-1021, 1985.
184. Song, B.-J., Gelboin, H. V., and Park, S. S., Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes, Science, 228, 490-492, 1985.
185. Fujino, T., Park, S. S., West, D., and Gelboin, H. V., Phenotyping of cytochrome P-450 in human tissues with monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 79, 3682-3686, 1982.
186. Pelkonen, O., Pasanen, M., Kuha, H., Gachalyi, B., Kairaluoma, M., Sotaniemi, E. A., Park, S. S., Friedman, F. K., and Gelboin, H. V., The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analysis with monoclonal antobodies, Br. J. Clin. Pharmacol., 22, 125-134, 1986.
187. Pasanen, M., Haaparanta, T., Sundin, M., Sivonen, P., Vähäkangas, K., Raunio, H., Hines, R., Gustafsson, J.-Å., and Pelkonen, O., Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent mono-oxygenase activities, Toxicology, 62, 175-187, 1990.
188. Manchester, D. K. and Jacoby, E. H., Sensitivity of human placental monooxygenase activities to maternal smoking, Clin. Pharmacol. Ther. 30, 687-692, 1981.
189. Pasanen, M., Taskinen, T., Sotaniemi, E. A., Kairaluoma, M., and Pelkonen, O., Inhibitor panel studies of human hepatic and placental cytochrome P-450-associated monooxygenase activities, Pharmacol. Toxicol., 62, 311-317, 1988.
190. Wong, T. K., Domin, B. A., Bent, P. E., Blanton, T. E., Anderson, M. W., and Philpot, R. M., Correlation of placental microsomal activities with protein detected by antibodies to rabbit cytochrome P-450 isozyme 6 in preparations from humans exposured to polychlorinated biphenyls, quaterphenyls, and dibenzofurans, Cancer Res., 46, 999-1004, 1986.
191. Pasanen, M., Stenbäck, F., Park, S. S., Gelboin, H. V., and Pelkonen, O., Immunohistochemical detection of human placental cytochrome P-450-associated mono-oxygenase system inducible by maternal cigarette smoking, Placenta, 9, 267-275, 1988.
192. Pasanen, M., Raunio, H., and Pelkonen, O., Freezing affects the activity and subcellular distribution profile of human placental xenobiotic- and steroid-metabolizing enzymes, Placenta, 6, 527-535, 1985.
193. Zhang, L., Connor, E.E., Chegini, N., and Shiverick, K. T., Modulation by benzo[a]pyrene of epidermal growth factor receptors, cell proliferation, and secretion of human chorionic gonadotropin in human placental cell lines, Biochem. Pharmacol., 50, 1171-1180, 1995.
194. Sesardic, D., Pasanen, M., Pelkonen, O., and Boobis, A. R., Differential expression and regulation of the members of the cytochrome P450IA gene subfamily in human tissues, Carcinogenesis, 11, 1183-1188, 1990.
195. Hakkola, J., Pasanen, M., Hukkanen, J., Pelkonen, O., Mäenpää, J., Edwards, R. J., Boobis, A. R., and Raunio, H., Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta, Biochem. Pharmacol., 51, 403-411, 1996.
196. Botto, F., Seree, E., Khyari, S. E., de Sousa, G., Massacrier, A., Placidi, M., Cau, P., Pellet, W., Rahmani, R., and Barra, Y., Tissue-specific expression and methylation of the human CYP2E1 gene, Biochem. Pharmacol., 48, 1095-1103, 1994.
197. Hakkola, J., Raunio, H., Purkunen, R., Pelkonen, O., Saarikoski, S., Cresteil, T., and Pasanen, M., Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy, Biochem. Pharmacol., 52, 379-383, 1996.
198. Rasheed, A., Hines, R. N., and McCarver-May, D. G., Variation in induction of human placental CYP2E1: Possible role is susceptibility to fetal alcohol syndrome, Toxicol. Appl. Pharmacol., 144, 396-400, 1997.
199. Schuetz, J. D., Kauma, S., and Guzelian, P. S., Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta, J. Clin. Invest., 92, 1018-1024, 1993.
200. Edwards, R. J., Singleton, A. M., Murray, B. P., Davies, D. S., and Boobis, A. R., Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes, Biochem. Pharmacol., 49, 39-47, 1995.
201. Murray, G. I., Barnes, T. S., Sewell, H. F., Ewen, S. W. B., Melvin, W. T., and Burke, M. D., The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450, Br. J. Clin. Pharmacol., 25, 465-475, 1988.
202. Pienimäki, P., Lampela, E., Hakkola, J., Arvela, P., Raunio, H., and Vähäkangas, K., Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta, Epilepsia, 38, 309-316, 1997.
203. Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore, M. W., Hinshelwood, M. M., Graham-Lorence, S., Amarneh, B., Ito, Y., Fisher, C. R., Michael, M. D., Mendelson, C. R., and Bulun, S. E., Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocrine Rev., 15, 342-355, 1994.
204. 18 reverse-phased cartridge for separation of tritiated water or steroid metabolites in placentas from both smoking and non-smoking mothers in vitro, Biol. Res. Pregn., 6, 94-99, 1985.
205. Meigs, R. A., The constitutive 7-ethoxycoumarin O-deethylase activity of human placental microsomes: relationship to aromatase, Biochem. Biophys. Res. Commun., 145, 1012-1018, 1987.
206. Sawada, M., Kitamura, R., Norose, T., Kitada, M., Itahashi, K., and Kamataki, T., Metabolic activation of aflatoxin B, by human placental microsomes, J. Toxicol. Sci., 18, 129-132, 1993.
207. Manchester, D. K., Gordon, S. K., Golas, C. L., Roberts, E. A., and Okey, A. B., Ah receptor in human placenta: stabilization by molybdate and characterization of binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methylcholanterene and benzo(a)pyrene, Cancer Res., 47, 4861-4868, 1987.
208. Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., and Bradfield, C. A., Cloning and expression of a human Ah receptor cDNA, Mol. Pharmacol., 44, 911-917, 1993.
209. Landers, J. P. and Bunce, N. J., The Ah receptor and the mechanism of dioxin toxicity, Biochem. J., 276, 273-287, 1991.
210. Sogawa, K., Nakano, R., Kobayashi, A., Kikuchi, Y., Ohe, N., Matsushita, N., and Fujii-Kuriyama, Y., Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation, Proc. Natl. Acad. Sci. USA, 92, 1936-1940, 1995.
211. Antonsson, C., Arulampalam, V., Whitelaw, M. L., Pettersson, S., and Poellinger, L., Constitutive function of the basic helix-loop-helix/PAS factor Arnt, J. Biol. Chem., 270, 13968-13972, 1995.
212. Swanson, H. I., Chan, W. K., and Bradfield, C. A., DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins, J. Biol. Chem., 270, 26292-26302, 1995.
213. Sutter, T. R., Guzman, K., Dold, K. M., and Greenlee, W. F., Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1β, Science, 254, 415-418, 1991.
214. Christou, M., Savas, Ü., Spink, D. C., Gierthy, J. F., and Jefcoate, C. R., Co-expression of human CYP1A1 and a human analog of cytochrome P450-EF in response to 2,3,7,8-tetrachloro-dibenzo-p-dioxin in human mammary carcinoma-derived MCF-7 cells, Carcinogenesis, 15, 725-732, 1994.
215. Gradin, K., Wilhelmsson, A., Poellinger, L., and Berghard, A., Nonresponsiveness of normal human fibroblasts to dioxin correlates with the presence of a constitutive xenobiotic response element-binding factor, J. Biol. Chem., 268, 4016-4068, 1993.
216. Pirani, B. B. K., Smoking during pregnancy, Obstet. Gynec. Survey, 33, 1-13, 1978.
217. Werler, M. M., Pober, B. R., and Holmes, L. B., Smoking and pregnancy, Teratology, 32, 473-481, 1985.
218. Everson, R. B., Randerath, E., Santella, R. M., Cefalo, R. C., Avitts, T. A., and Randerath, K., Detection of smoking-related covalent DNA adducts in human placenta, Science, 231, 54-57, 1986.
219. Manchester, D. K., Weston, A., Choi, J.-S., Trivers, G. E., Fennessey, P. V., Quintana, E., Farmer, P. B., Mann, D. L., and Harris, C. C., Detection of benzo[a]pyrene diol epoxide-DNA adducts in human placenta, Proc. Natl. Acad. Sci. USA, 85, 9243-9247, 1988.
220. 32P-postlabeling analysis of human placental DNA known to contain benzo[α]pyrene diol epoxide adducts, Carcinogenesis, 11, 553-559, 1990.
221. Manchester, D., Bowman, E. D., Parker, N. B., Caporaso, N. E., and Weston, A., Determinants of polycyclic aromatic hydrocarbon-DNA adducts in human placenta, Cancer Res., 52, 1499-1503, 1992.
222. Vähäkangas, K., Raunio, H., Pasanen, M., Sivonen, P., Park, S.-S., Gelboin, H. V., and Pelkonen, O., Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: evidence for the involvement of P-450IA1 and P-450IA2, J. Biochem. Toxicol., 4, 79-86, 1989.
223. Hansen, C., Asmussen, I., and Autrup, H., Detection of carcinogen-DNA adducts in human fetal tissues by the 32-postlabeling procedure, Environ. Health Perspect., 99, 229-231, 1993.
224. Gallagher, J. E., Everson, R. B., Lewtas, J., George, M., and Lucier, G. W., Comparison of DNA adduct levels in human placenta from polychlorinated biphenyl exposed wom-en and smokers in which CYP 1A1 levels are similarly elevated, Teratog. Carcinog. Mutagen., 183-192, 1994.
225. Hatch, M. C., Warburton, D., and Santella, R. M., Polycyclic aromatic hydrocarbon-DNA adducts in spontaneously aborted fetal tissue, Carcinogenesis, 11, 1673-1675, 1990.
226. Hansen, C., Sorensen, L. D., Asmussen, I., and Autrup, H., Transplacental exposure to tobacco smoke in human-adduct formation in placenta and umbilical cord blood vessels, Teratog. Carcinog. Mutagen., 12, 51-60, 1992.
227. Pelkonen, O., Kärki, N. T., Koivisto, M., Tuimala, R., and Kauppila, A., Maternal cigarette smoking, placental aryl hydrocarbon hydroxylase and neonatal size, Toxicol. Lett. 3, 331-335, 1979.
228. Everson, R. B., Randerath, E., Santella, R., Avitts, T. A., Weinstein, I. B., and Randerath, K., Quantitative associations between DNA damage in human placenta, maternal smoking, and birth weight, J. Natl. Cancer Inst., 80, 567-576, 1988.
229. Huel, G., Girard, F., Nessmann, C., Godin, J., Blot, P., Breart, G., and Moreau, T., Placental aryl hydrocarbon hydroxylase activity and placental calcifications, Toxicology, 71, 257-266, 1992.
230. Manchester, D. and Jacoby, E., Decreased placental monooxygenase activities associated with birth defects, Teratology, 30, 31-37, 1984.
231. Manchester, D. K., Parker, N. B., and Bowman, C. M., Maternal smoking increases xenobiotic metabolism in placenta but not umbilical vein endothelium, Pediatr. Res., 18, 1071-1075, 1984.
232. Fisk, N. M. and Storey, G. N. B., Fetal outcome in obstetric cholestasis, Br. J. Obstet. Gynaecol., 95, 1137-1143, 1988.
233. Pasanen, M., Helin-Martikainen, H.-L., Pelkonen, O., and Kirkinen, P., Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro, Placenta, 18, 37-41, 1997.
234. Ostrea, E. M., Porter, T., Balun, J., Wardell, J. N., and Bottoms, S., Effect of chronic maternal drug addiction on placental drug metabolism, Dev. Pharmacol. Ther., 12, 42-48, 1989.
235. Pineau, T., Fernandez-Salguero, P., Lee, S. S. T., McPhail, T., Ward, J. M., and Gonzalez, F. J., Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450IA2, Proc. Natl. Acad. Sci. USA, 92, 5134-5138, 1995.
236. Liang, H.-C. L., Li, H., McKinnon, R. A., Duffy, J. J., Potter, S. S., Puga, A., and Nebert, D. W., CYP1a2(-/-) null mutant mice develop normally but show deficient drug metabolism, Proc. Natl. Acad. Sci. USA, 93, 1671-1676, 1996.
237. Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., and Gonzalez, F. J., Role of CYP2E1 in the hepatotoxicity of acetaminophen, J. Biol. Chem., 271, 12063-12067, 1996.
238. Zaphiropoulos, P. G., Mode, A., Norstedt, G., and Gustaffson, J.-Å., Regulation of sexual differentiation in drug and steroid metabolism, Trends Pharmacol. Sci., 10, 149-153, 1989.
239. Fujita, I., Sindhu, R. K., and Kikkawa, Y., Hepatic cytochrome P450 enzyme imprinting in adult rat by neonatal benzo(a)pyrene administration, Pediatr. Res., 37, 646-651, 1995.
240. Park, B. K., Pirmohamed, M., and Kitteringham, N. R., The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity, Pharmac. Ther., 68, 385-424, 1995.